| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TLXTelix Pharmaceuticals Limited | 2.49B | 7.43 | 53.07 | 55.85% | 3.98% | 15.63% | 0.36% | 1.02 |
| EXELExelixis, Inc. | 12.18B | 45.44 | 25.82 | 18.49% | 29.63% | 31.37% | 5.2% | 0.09 |
| BBOTBridgeBio Oncology Therapeutics Inc. | 919.87M | 11.50 | 25 | -25.73% | ||||
| INBXInhibrx Biosciences, Inc. | 1.04B | 71.80 | 0.62 | -88.89% | -110.78% | -421.09% | 0.06 | |
| NUVBNuvation Bio Inc. | 2.1B | 6.14 | -2.91 | -8.13% | -66.74% | 0.02 | ||
| RLAYRelay Therapeutics, Inc. | 1.32B | 7.63 | -3.23 | -60.83% | -26.71% | -48.97% | 0.06 | |
| ORICORIC Pharmaceuticals, Inc. | 1.12B | 11.52 | -6.30 | -33.24% | 0.01 | |||
| ZLABZai Lab Limited | 2.09B | 18.82 | -7.24 | 49.59% | -46.83% | -27.21% | 0.18 |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 2.06M | 7.14M | 13.8M | 10.39M | 11.7M | 14.46M | 26.98M | 35.27M |
| Revenue Growth % | - | - | 2.46% | 0.93% | -0.25% | 0.13% | 0.24% | 0.87% | 0.31% |
| Cost of Goods Sold | 269.29K | 11.87M | 20.76M | 25.54M | 33.15M | 0 | 0 | 156.5M | 172.97M |
| COGS % of Revenue | - | 5.76% | 2.91% | 1.85% | 3.19% | - | - | 5.8% | 4.9% |
| Gross Profit | -269.29K | -9.81M | -13.63M | -11.74M | -22.76M | 11.7M | 14.46M | -129.52M | -137.69M |
| Gross Margin % | - | -4.76% | -1.91% | -0.85% | -2.19% | 1% | 1% | -4.8% | -3.9% |
| Gross Profit Growth % | - | -35.41% | -0.39% | 0.14% | -0.94% | 1.51% | 0.24% | -9.96% | -0.06% |
| Operating Expenses | 13.22M | 18.27M | 28.88M | 14.56M | 29.2M | 77.31M | 131.12M | 60.43M | 72.18M |
| OpEx % of Revenue | - | 8.87% | 4.05% | 1.05% | 2.81% | 6.61% | 9.07% | 2.24% | 2.05% |
| Selling, General & Admin | 3.45M | 6.41M | 8.12M | 14.56M | 29.2M | 32.44M | 49.51M | 59.83M | 71.46M |
| SG&A % of Revenue | - | 3.11% | 1.14% | 1.05% | 2.81% | 2.77% | 3.42% | 2.22% | 2.03% |
| Research & Development | 9.77M | 11.87M | 20.76M | 31.64M | 33.15M | 44.88M | 81.61M | 156.5M | 172.97M |
| R&D % of Revenue | - | 5.76% | 2.91% | 2.29% | 3.19% | 3.84% | 5.64% | 5.8% | 4.9% |
| Other Operating Expenses | 0 | -119K | -665K | -31.64M | -33.15M | 0 | 0 | -155.9M | -172.25M |
| Operating Income | -13.49M | -16.21M | -21.75M | -26.3M | -51.96M | -65.62M | -116.65M | -189.95M | -209.87M |
| Operating Margin % | - | -7.87% | -3.05% | -1.91% | -5% | -5.61% | -8.07% | -7.04% | -5.95% |
| Operating Income Growth % | - | -0.2% | -0.34% | -0.21% | -0.98% | -0.26% | -0.78% | -0.63% | -0.1% |
| EBITDA | -13.22M | -15.88M | -21.04M | -25.34M | -50.68M | -64.21M | -112.96M | -183.4M | -202.69M |
| EBITDA Margin % | - | -7.71% | -2.95% | -1.84% | -4.88% | -5.49% | -7.81% | -6.8% | -5.75% |
| EBITDA Growth % | - | -0.2% | -0.32% | -0.2% | -1% | -0.27% | -0.76% | -0.62% | -0.11% |
| D&A (Non-Cash Add-back) | 269.29K | 335.56K | 710.8K | 960K | 1.28M | 1.41M | 3.69M | 6.55M | 7.18M |
| EBIT | -13.53M | -16.21M | -22.24M | -26.3M | -51.96M | -65.5M | -110.9M | -189.95M | -172.07M |
| Net Interest Income | 0 | 50K | 169K | 814K | 226K | -2.86M | 2.41M | 10.74M | 32.55M |
| Interest Income | 8K | 50K | 169K | 814K | 683K | 120K | 5.76M | 14M | 34.28M |
| Interest Expense | 0 | 0 | 0 | 0 | 457K | 2.98M | 3.34M | 3.26M | 1.73M |
| Other Income/Expense | -37.9K | -69K | -496K | -4.56M | 226K | -2.86M | 2.41M | 10.74M | 36.08M |
| Pretax Income | -13.53M | -16.28M | -22.24M | -30.86M | -51.73M | -68.48M | -114.24M | -179.21M | -173.8M |
| Pretax Margin % | - | -7.9% | -3.12% | -2.24% | -4.98% | -5.85% | -7.9% | -6.64% | -4.93% |
| Income Tax | -20.94K | -23K | -396K | -254K | -724K | -1.66M | -1.52M | 1.46M | -4.76M |
| Effective Tax Rate % | 1% | 1% | 0.98% | 0.99% | 0.99% | 0.98% | 0.99% | 1.01% | 0.97% |
| Net Income | -13.51M | -16.26M | -21.85M | -30.61M | -51.01M | -66.82M | -112.72M | -180.66M | -169.03M |
| Net Margin % | - | -7.89% | -3.06% | -2.22% | -4.91% | -5.71% | -7.79% | -6.7% | -4.79% |
| Net Income Growth % | - | -0.2% | -0.34% | -0.4% | -0.67% | -0.31% | -0.69% | -0.6% | 0.06% |
| Net Income (Continuing) | -13.51M | -16.26M | -21.85M | -30.61M | -51.01M | -66.82M | -112.72M | -180.66M | -169.03M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.76 | -1.22 | -1.64 | -2.77 | -2.66 | -2.67 | -3.80 | -5.08 | -2.90 |
| EPS Growth % | - | -0.61% | -0.34% | -0.69% | 0.04% | -0% | -0.42% | -0.34% | 0.43% |
| EPS (Basic) | -0.76 | -1.22 | -1.64 | -2.77 | -2.66 | -2.67 | -3.80 | -5.08 | -2.91 |
| Diluted Shares Outstanding | 17.7M | 13.29M | 13.29M | 11.05M | 19.15M | 25.06M | 29.66M | 35.59M | 58.21M |
| Basic Shares Outstanding | 17.7M | 13.29M | 13.29M | 11.05M | 19.15M | 25.06M | 29.66M | 35.59M | 58.21M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 11.29M | 71.51M | 76.77M | 104.15M | 155.72M | 458.56M | 369.38M | 561.87M | 928.61M |
| Cash & Short-Term Investments | 9.4M | 67.66M | 63.38M | 92.12M | 135.99M | 438.68M | 339.15M | 526.42M | 879.52M |
| Cash Only | 9.4M | 67.66M | 63.38M | 92.12M | 135.99M | 438.68M | 339.15M | 526.42M | 879.52M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 1.37M | 3M | 11.31M | 7.14M | 14.63M | 11.91M | 21.21M | 24.04M | 35.65M |
| Days Sales Outstanding | - | 531.73 | 578.65 | 188.97 | 514.06 | 371.65 | 535.2 | 325.26 | 368.91 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 1.37M | 0 | 0 | 0 | 0 | 0 | 9.02M | 11.41M | 13.43M |
| Total Non-Current Assets | 549K | 2.49M | 4.86M | 6.05M | 5.43M | 21.24M | 41.23M | 33.48M | 28.26M |
| Property, Plant & Equipment | 519K | 1.36M | 1.82M | 4.35M | 3.61M | 17.79M | 32.77M | 27.68M | 17.19M |
| Fixed Asset Turnover | - | 1.51x | 3.93x | 3.17x | 2.88x | 0.66x | 0.44x | 0.97x | 2.05x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 547K | 547K |
| Other Non-Current Assets | 30K | 1.13M | 3.04M | 1.7M | 1.82M | 3.45M | 8.46M | 5.24M | 10.53M |
| Total Assets | 11.84M | 74M | 81.63M | 110.19M | 161.15M | 479.79M | 410.61M | 595.34M | 956.87M |
| Asset Turnover | - | 0.03x | 0.09x | 0.13x | 0.06x | 0.02x | 0.04x | 0.05x | 0.04x |
| Asset Growth % | - | 5.25% | 0.1% | 0.35% | 0.46% | 1.98% | -0.14% | 0.45% | 0.61% |
| Total Current Liabilities | 3.81M | 9.45M | 8.93M | 8.82M | 23.13M | 36.24M | 53.34M | 69.54M | 67.23M |
| Accounts Payable | 1.88M | 2.06M | 1.89M | 1.95M | 1.36M | 2.72M | 6.47M | 13.05M | 15.79M |
| Days Payables Outstanding | 2.55K | 63.52 | 33.18 | 27.85 | 15.03 | - | - | 30.44 | 33.33 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.88M | 0 |
| Deferred Revenue (Current) | 0 | 1000K | 10K | 728K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Other Current Liabilities | 1.54M | 148K | 5.42M | 2.58M | 6.39M | 7M | 13.4M | 13.24M | 35.74M |
| Current Ratio | 2.96x | 7.57x | 8.60x | 11.81x | 6.73x | 12.65x | 6.92x | 8.08x | 13.81x |
| Quick Ratio | 2.96x | 7.57x | 8.60x | 11.81x | 6.73x | 12.65x | 6.92x | 8.08x | 13.81x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 111.73M | 142.52M | 8.18M | 42.56M | 97.3M | 86.48M | 154.88M | 96.58M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 14.51M | 29.87M | 30.32M | 30.7M | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 1.25M | 426K | 12.08M | 10.88M | 9.38M | 3.99M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 101.25M | 127.9M | 2M | 2.61M | 3.28M | 3.83M | 4.58M | 1.12M |
| Total Liabilities | 3.81M | 121.19M | 151.45M | 17M | 65.69M | 133.54M | 139.83M | 224.41M | 163.81M |
| Total Debt | 0 | 0 | 0 | 1.89M | 15.78M | 44.34M | 44.33M | 44.96M | 9.49M |
| Net Debt | -9.4M | -67.66M | -63.38M | -90.23M | -120.22M | -394.34M | -294.83M | -481.47M | -870.03M |
| Debt / Equity | - | - | - | 0.02x | 0.17x | 0.13x | 0.16x | 0.12x | 0.01x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | -113.70x | -21.99x | -34.88x | -58.21x | -121.31x |
| Total Equity | 8.02M | -47.18M | -69.83M | 93.2M | 95.46M | 346.25M | 270.78M | 370.93M | 793.06M |
| Equity Growth % | - | -6.88% | -0.48% | 2.33% | 0.02% | 2.63% | -0.22% | 0.37% | 1.14% |
| Book Value per Share | 0.45 | -3.55 | -5.25 | 8.44 | 4.99 | 13.82 | 9.13 | 10.42 | 13.62 |
| Total Shareholders' Equity | 8.02M | -47.18M | -69.83M | 93.2M | 95.46M | 346.25M | 270.78M | 370.93M | 793.06M |
| Common Stock | 3K | 5K | 10K | 227K | 266K | 384K | 387K | 550K | 890K |
| Retained Earnings | -31.84M | -48.1M | -69.94M | -100.55M | -151.56M | -218.38M | -331.1M | -511.76M | -680.79M |
| Treasury Stock | 0 | -837K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -2.29M | 69K | -1.75M | -1.53M | -3.19M | -3.39M | 387K | -1.3M | 119K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -11.27M | -1.42M | -26.08M | -28.61M | -17.79M | -14.79M | -86.11M | -60.63M | -164.72M |
| Operating CF Margin % | - | -0.69% | -3.65% | -2.07% | -1.71% | -1.26% | -5.95% | -2.25% | -4.67% |
| Operating CF Growth % | - | 0.87% | -17.43% | -0.1% | 0.38% | 0.17% | -4.82% | 0.3% | -1.72% |
| Net Income | -13.51M | -16.26M | -21.85M | -30.61M | -51.01M | -66.82M | -112.72M | -180.66M | -169.03M |
| Depreciation & Amortization | 269.29K | 332K | 712K | 960K | 1.28M | 1.41M | 3.69M | 6.55M | 7.17M |
| Stock-Based Compensation | 123K | 515K | 1.02M | 3.08M | 6.51M | 12.08M | 26.78M | 32.48M | 38.08M |
| Deferred Taxes | 0 | 119K | 0 | 0 | -673K | -1.67M | -4.98M | 3.31M | -5.23M |
| Other Non-Cash Items | 182.52K | 856K | 665K | 5.38M | 751K | 2.14M | 442K | 1.04M | -2.26M |
| Working Capital Changes | 1.85M | 13.02M | -6.63M | -7.43M | 25.35M | 38.06M | 672K | 76.66M | -33.46M |
| Change in Receivables | -1.16M | -1.42M | -400K | 4.91M | -2.15M | 4.54M | -11.35M | -1.2M | -11.95M |
| Change in Inventory | 0 | 0 | -2.12M | -2.55M | 4.16M | -4.79M | 0 | 0 | 0 |
| Change in Payables | 1.64M | 67K | -169K | 220K | -663K | 1.2M | 2.56M | 8M | 3.1M |
| Cash from Investing | -243.36K | -1.11M | -1.19M | -1.55M | -1.2M | -2.03M | -18.99M | -2.93M | -1.24M |
| Capital Expenditures | -243.36K | -1.11M | -1.19M | -1.55M | -1.2M | -2.03M | -18.99M | -2.93M | -1.24M |
| CapEx % of Revenue | - | 0.54% | 0.17% | 0.11% | 0.12% | 0.17% | 1.31% | 0.11% | 0.04% |
| Acquisitions | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 16.77M | 57.88M | 25.43M | 58.44M | 62.84M | 320.73M | 6.69M | 250.03M | 519.75M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - |
| Other Financing | 16.77M | 1K | 1K | 149K | -301K | 7.18M | 989K | 682K | 7.53M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -11.51M | -2.53M | -27.26M | -30.17M | -18.99M | -16.82M | -105.1M | -63.56M | -165.96M |
| FCF Margin % | - | -1.23% | -3.82% | -2.19% | -1.83% | -1.44% | -7.27% | -2.36% | -4.7% |
| FCF Growth % | - | 0.78% | -9.78% | -0.11% | 0.37% | 0.11% | -5.25% | 0.4% | -1.61% |
| FCF per Share | -0.65 | -0.19 | -2.05 | -2.73 | -0.99 | -0.67 | -3.54 | -1.79 | -2.85 |
| FCF Conversion (FCF/Net Income) | 0.83x | 0.09x | 1.19x | 0.93x | 0.35x | 0.22x | 0.76x | 0.34x | 0.97x |
| Interest Paid | 0 | 0 | 0 | 0 | 378K | 2.52M | 2.79M | 2.75M | 1.37M |
| Taxes Paid | 0 | 0 | 73K | 117K | 124K | 73K | 2.23M | 562K | 792K |
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -168.37% | - | - | -261.92% | -54.08% | -30.25% | -36.53% | -56.31% | -29.04% |
| Return on Invested Capital (ROIC) | - | - | - | -663.67% | - | - | - | - | - |
| Gross Margin | - | -476.02% | -190.93% | -85.06% | -219.05% | 100% | 100% | -480.13% | -390.34% |
| Net Margin | - | -789.27% | -306.14% | -221.78% | -490.95% | -571.25% | -779.35% | -669.72% | -479.18% |
| Debt / Equity | - | - | - | 0.02x | 0.17x | 0.13x | 0.16x | 0.12x | 0.01x |
| Interest Coverage | - | - | - | - | -113.70x | -21.99x | -34.88x | -58.21x | -121.31x |
| FCF Conversion | 0.83x | 0.09x | 1.19x | 0.93x | 0.35x | 0.22x | 0.76x | 0.34x | 0.97x |
| Revenue Growth | - | - | 246.41% | 93.4% | -24.72% | 12.58% | 23.65% | 86.52% | 30.76% |
Bicycle Therapeutics plc (BCYC) reported $28.3M in revenue for fiscal year 2024.
Bicycle Therapeutics plc (BCYC) grew revenue by 30.8% over the past year. This is strong growth.
Bicycle Therapeutics plc (BCYC) reported a net loss of $250.7M for fiscal year 2024.
Bicycle Therapeutics plc (BCYC) has a return on equity (ROE) of -29.0%. Negative ROE indicates the company is unprofitable.
Bicycle Therapeutics plc (BCYC) had negative free cash flow of $242.2M in fiscal year 2024, likely due to heavy capital investments.